NCT02790736

Brief Intervention to Reduce Fear of Public Speaking

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: New York State Psychiatric Institute · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The study will test the efficacy of propranolol or placebo, administered after retrieval of a previously acquired public speaking fear, in reducing fear and avoidance of public speaking.

Detailed description

Twenty subjects with Performance-Only type of Social Anxiety Disorder will be enrolled in the study. Participants will complete baseline assessments of fear and avoidance of public speaking. Participants will be randomly assigned to a single dose of propranolol 40mg or placebo, administered immediately after a fear activation procedure. Primary outcome assessment will be self-reported fear of public speaking and avoidance behavior in a behavioral avoidance task 2 weeks after the intervention.

Conditions

• Social Anxiety Disorder

Interventions

Type	Name	Description
DRUG	propranolol	active treatment
DRUG	Placebo	inactive pill

Timeline

• Start date: 2016-06-01
• Primary completion: 2020-10-30
• Completion: 2020-10-30
• First posted: 2016-06-06
• Last updated: 2023-06-07
• Results posted: 2018-09-05

Locations

1 site across 1 country: United States